Program
Palivizumab
Also written as “Palivizumab 15 mg/kg”, “Lyophilized Palivizumab” and “Liquid Palivizumab”.
Its studies are mostly in Respiratory Syncytial Virus Infections · Bronchopulmonary Dysplasia · Bronchiolitis, led by 5 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| AstraZeneca | 41 open or running | phase 4since Oct 3, 2005 | Oct 3, 2005 | Feb 28, 2027NCT06851806 |
| AbbVie | 20 open or running | phase 3since Sep 12, 2011 | Sep 12, 2011 | none ahead |
| Abbott | 10 open or running | phase 3since Nov 2, 2009 | Nov 2, 2009 | none ahead |
| Fresenius Kabi | 10 open or running | phase 1since Jul 24, 2020 | Jul 24, 2020 | none ahead |
| Hamad Medical | 10 open or running | phase 3since May 10, 2015 | May 10, 2015 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 3, 2005First study: phase 4 study in Chronic Lung DiseaseNew to AstraZenecaAstraZeneca · NCT00233064 · 417 enrolled · United States
- Oct 14, 2005Phase 2 study in -Unhealthy Children With a History of PrematurityAstraZeneca · NCT00240929 · 150 enrolled · United States
- Apr 18, 2006Phase 2 study in Respiratory Syncytial Virus InfectionsAstraZeneca · NCT00316264 · 260 enrolled · Australia, Chile, New Zealand
- Nov 2, 2009Abbott's first study: phase 3 study in Respiratory Syncytial Virus InfectionsNew to AbbottAbbott · NCT01006629 · 100 enrolled · Russian Federation
- Sep 12, 2011AbbVie's first study: phase 3 study in Respiratory Syncytial Virus InfectionsNew to AbbVieAbbVie · NCT01466062 · 28 enrolled · Japan
- May 10, 2015Hamad Medical's first study: phase 3 study in BronchiolitisNew to Hamad MedicalHamad Medical · NCT02442427 · 420 enrolled · Qatar
- Nov 16, 2016Phase 3 study in Bronchopulmonary DysplasiaAbbVie · NCT02968173 · 50 enrolled
- Jul 24, 2020Fresenius Kabi's first study: phase 1 study in Healthy Adult ParticipantsNew to Fresenius KabiFresenius Kabi · NCT04540627 · 56 enrolled · United Kingdom
- Feb 10, 2025No phase study in Respiratory Syncytial Virus (RSV)AstraZeneca · NCT06851806 · 21 enrolled · India
Ahead
- Feb 28, 2027Primary completion: no phase study in Respiratory Syncytial Virus (RSV)AstraZeneca · NCT06851806
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Fusion glycoprotein F0 inhibitor”ChEMBL 37, by rule
Studies
All 9 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06851806Respiratory Syncytial Virus (RSV) · India | – | Active, not recruiting | AstraZeneca | Feb 28, 2027 | 21 |
| NCT04540627Healthy Adult Participants · United Kingdom | 1 | Completed | Fresenius Kabi | Oct 23, 2020 | 56 |
| NCT02968173Bronchopulmonary Dysplasia | 3 | Completed | AbbVie | Jul 13, 2017 | 50 |
| NCT02442427Bronchiolitis · Qatar | 3 | Completed | Hamad Medical | Feb 1, 2018 | 420 |
| NCT01466062Respiratory Syncytial Virus Infections · Japan | 3 | Completed | AbbVie | Apr 2012 | 28 |
| NCT01006629Respiratory Syncytial Virus Infections · Russian Federation | 3 | Completed | Abbott | Apr 2010 | 100 |
| NCT00316264Respiratory Syncytial Virus Infections · Australia, Chile, New Zealand | 2 | Completed | AstraZeneca | Feb 2007 | 260 |
| NCT00240929-Unhealthy Children With a History of Prematurity · United States | 2 | Completed | AstraZeneca | 150 | |
| NCT00233064Chronic Lung Disease · United States | 4 | Completed | AstraZeneca | Oct 2007 | 417 |
How it is read
Names in the registry
- “Palivizumab”, 4 entries
- “Palivizumab 15 mg/kg”, 1 entry
- “Lyophilized Palivizumab”, 1 entry
- “Liquid Palivizumab”, 1 entry
- “Motavizumab, palivizumab”, 1 entry
Conditions, from the studies’ own filings
- Respiratory Syncytial Virus Infections, 3 studies
- Bronchopulmonary Dysplasia, 1 study
- Bronchiolitis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.